Cara Therapeutics Inc (NAS:CARA)
$ 0.2908 -0.0132 (-4.34%) Market Cap: 15.95 Mil Enterprise Value: -21.94 Mil PE Ratio: 0 PB Ratio: 29.08 GF Score: 33/100

Cara Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 16, 2019 / 12:00AM GMT
Release Date Price: $19.16 (+2.41%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Thanks so much for joining. We'll get moving to our next company presenter. My name is Jason Gerberry. I'm the U.S. pharma analyst at Bank of America. I'm pleased to be introducing Cara Therapeutics. I'm joined by Derek Chalmers, CEO; and Mani Mohindru, CFO. So thank you for joining us here at the conference.

Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks for the invitation.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Yes, of course. Of course. Maybe, Derek, I don't know if you want to maybe just provide a quick overview on the company? The late-stage programs, what you feel like makes Cara an interesting story.

Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director

Yes. Sure. So we're a company focused on the development of an entirely novel class of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot